Hims & Hers Health (NYSE:HIMS) CFO Sells $876,846.15 in Stock

Posted by Francis Steltz on Sep 26th, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 29,277 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $29.95, for a total value of $876,846.15. Following the sale, the chief financial officer owned 236,527 shares in the company, valued at $7,083,983.65. The trade was a 11.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total value of $354,860.66.
On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.99, for a total value of $148,090.62.
On Monday, August 17th, Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.89, for a total value of $261,831.32.
On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.49, for a total value of $261,377.87.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $29.46 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The firm has a market capitalization of $6.87 billion, a PE ratio of -46.76 and a beta of 2.42. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $65.30. The business’s fifty day moving average price is $29.54 and its two-hundred day moving average price is $28.07.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue was up 38.2% compared to the same quarter last year. During the same period last year, the firm posted $0.17 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after buying an additional 2,877,550 shares in the last quarter. Norges Bank acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at $62,153,000. Clear Street Group Inc. lifted its holdings in shares of Hims & Hers Health by 23.6% in the fourth quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after buying an additional 363,893 shares during the period. Finally, State of Michigan Retirement System boosted its stake in Hims & Hers Health by 13.7% during the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock valued at $48,549,000 after buying an additional 280,900 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the subject of several recent analyst reports. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a research report on Friday, September 11th. They set a “neutral” rating and a $32.00 price objective for the company. Barclays decreased their price objective on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Finally, Morgan Stanley raised their target price on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $32.43.

View Our Latest Research Report on Hims & Hers Health

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Hims & Hers launched an AI-native weight-loss care platform featuring a closed-loop action engine and clinical escalation. The initiative could improve treatment personalization, operating efficiency and customer retention, although its financial impact has not yet been quantified. AI-native weight-loss platform article
Neutral Sentiment: CFO Oluyemi Okupe sold 29,277 shares valued at approximately $876,846 under a pre-arranged Rule 10b5-1 trading plan. He retained 236,527 shares, making the transaction a limited sentiment concern rather than a clear signal of deteriorating company prospects. CFO stock sale article
Negative Sentiment: Multiple law firms are promoting a securities-fraud class action against Hims & Hers and certain executives. The allegations stem from the FTC’s complaint concerning privacy practices, subscription cancellations and prescription billing, with investors claiming the company failed to disclose material risks. The deadline to seek lead-plaintiff status is November 2, 2026. Potential legal costs, reputational damage and regulatory remedies are weighing on the investment case. Hims & Hers securities class action article
Negative Sentiment: Profitability is another vulnerability: the latest reported quarter included a $0.37-per-share loss versus an expected $0.05 loss, despite revenue of $753.2 million exceeding estimates. High short interest and elevated volatility may amplify market reactions to further legal, regulatory or earnings developments. Hims & Hers legal pressure and stock decline article

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.